Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
MWN-AI** Summary
Prothena Corporation plc (NASDAQ: PRTA) has announced a significant milestone in its partnership with Novo Nordisk, earning a $50 million payment upon reaching a prespecified enrollment target in the Phase 3 CLEOPATTRA clinical trial for coramitug (formerly PRX004). This investigational antibody is being evaluated as a potential first-in-class treatment for transthyretin amyloidosis (ATTR) with cardiomyopathy (ATTR-CM). To date, Prothena has accumulated $150 million of the total $1.2 billion available through milestone payments outlined in the agreement with Novo Nordisk, which acquired the ATTR amyloidosis business from Prothena in July 2021.
The CLEOPATTRA trial aims to assess coramitug in approximately 1,280 participants suffering from ATTR-CM, with the primary completion anticipated by 2029. Coramitug operates through a unique mechanism to deplete pathogenic amyloid deposits associated with the disease, effectively improving organ function while sparing the native tetrameric form of the transthyretin protein. This differentiates coramitug from existing therapies that primarily stabilize or reduce production of native transthyretin.
Previous Phase 2 trial results indicated promising outcomes whereby patients treated with coramitug showed a significant reduction in NT-proBNP, alongside improvements in echocardiographic measurements of cardiac function. Patients in this trial were largely already being treated with standard care for ATTR-CM, highlighting the potential complementary role of coramitug.
Prothena, a clinical biotechnology company specializing in protein dysregulation, is advancing a robust pipeline of therapies aimed at a variety of severe neurodegenerative and rare diseases. The company continues to leverage extensive scientific expertise in targeting misfolded proteins to develop innovative treatments. For further information, visit Prothena's website or follow the company on social media.
MWN-AI** Analysis
**Market Analysis and Advice on Prothena Corporation (NASDAQ: PRTA)**
Prothena Corporation has achieved a significant clinical milestone by securing a $50 million payment from Novo Nordisk for reaching the enrollment target in the Phase 3 CLEOPATTRA clinical trial for coramitug (formerly PRX004). This achievement raises the total milestone payments received by Prothena from Novo Nordisk to $150 million of the potential $1.2 billion agreement. Coramitug is positioned as a promising first-in-class amyloid depleter antibody targeting ATTR amyloidosis with cardiomyopathy, a serious and often underdiagnosed condition.
The market's response to this milestone is crucial. Coramitug's differentiated mechanism, which aims to deplete amyloid deposits without affecting the normal protein structure, may provide a strong competitive advantage in the therapeutic landscape. The Phase 2 trial results, demonstrating significant improvements in NT-proBNP levels and echocardiographic parameters, bolster the therapeutic potential of coramitug, enhancing market sentiment towards Prothena.
Investors should consider the following factors when evaluating Prothena’s stock:
1. **Clinical Milestones**: Continued progress in the CLEOPATTRA trial could unlock further milestone payments and increase investor confidence. Monitoring enrollment and outcome data up to the primary completion date in 2029 will be pivotal.
2. **Partnership with Novo Nordisk**: The alliance provides Prothena not only with financial backing but also with the strength of Novo Nordisk's global resources and expertise, enhancing the chances of successful commercialization.
3. **Market Position**: As an innovative player in treating rare diseases like ATTR amyloidosis, Prothena is well-positioned to benefit from increasing attention and investment in biotechnology.
In conclusion, investors should remain optimistic about Prothena's trajectory, particularly in light of recently positive developments. However, they should also remain cognizant of potential market volatility and the long timeframes typically associated with biotech clinical trials. Continuous monitoring of clinical progress and market developments will be essential for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3
- Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nordisk
Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial evaluating coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Novo Nordisk is evaluating coramitug in the ongoing Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM with primary completion expected in 2029 ( NCT07207811 ).
Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021. Under the terms of the acquisition agreement, Prothena is eligible to receive up to $1.2 billion upon achievement of clinical development and sales milestones, including $150 million earned to date.
About Coramitug (formerly PRX004)
Coramitug (formerly PRX004) is an investigational antibody designed to deplete amyloid associated with disease pathology in hereditary and wild type ATTR amyloidosis, without affecting the native, normal tetrameric form of the protein 1-3 . Coramitug’s proposed mechanism of action is to deplete both the deposited amyloid to improve organ function and circulating non-native TTR to prevent further organ deposition 1-3 . This differentiated depleter mechanism of action could be developed as a monotherapy approach to ATTR amyloidosis and might also complement existing therapeutic approaches which either stabilize or reduce production of the native TTR tetramer 3 .
In a Phase 2 clinical trial conducted by Novo Nordisk, coramitug 60 mg/kg significantly reduced NT-proBNP in a patient population predominantly in which the vast majority (>80%) were already receiving standard of care treatment for ATTR-CM. Furthermore, compared with placebo, coramitug was associated with improvements in multiple echocardiographic parameters of cardiac function, and was well-tolerated in participants with ATTR-CM. These findings support the potential of coramitug as an amyloid-clearing immunotherapy for ATTR-CM and provide a rationale for additional clinical investigation of coramitug for the treatment of patients with ATTR-CM 4 .
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying its proprietary CYTOPE ® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, design, and proposed mechanism of action coramitug; plans for ongoing and future clinical trials of coramitug; and amounts we might receive under our agreement with Novo Nordisk. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
References:
1 Preclinical studies of PRX004 (coramitug) – data on file
2 Higaki JN et al. Amyloid , 2016
3 Suhr OB et al. Amyloid , 2025
4 Fontana M et al. Circulation , 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20260309588944/en/
Mark Johnson, CFA
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
IR@prothena.com
Media@prothena.com
FAQ**
Given the recent $50 million milestone payment, how does Prothena Corporation plc (NASDAQ:PRTA) anticipate the ongoing Phase 3 CLEOPATTRA trial outcomes will impact its financial projections and future milestone earnings?
What specific challenges or risks does Prothena Corporation plc (NASDAQ:PRTA) foresee in the continued development of coramitug, especially considering the competitive landscape of ATTR amyloidosis treatments?
How does Prothena Corporation plc (NASDAQ:PRTA) plan to leverage the data from the Phase 2 trial results of coramitug to attract potential investors or partners for future clinical trials and commercialization?
Can Prothena Corporation plc (NASDAQ:PRTA) provide insights into the potential revenue generation from the total eligible milestone payments under its agreement with Novo Nordisk, particularly if coramitug proves successful?
**MWN-AI FAQ is based on asking OpenAI questions about Prothena Corporation plc (NASDAQ: PRTA).
NASDAQ: PRTA
PRTA Trading
1.92% G/L:
$10.08 Last:
347,077 Volume:
$10.21 Open:
